Recent advances in novel atypical antipsychotic agents: potential therapeutic agents for the treatment of schizophrenia

Bibliography

• MATTHYSE S: Antipsychotic drug actions: a clue to the neuropathology of schizophrenia? Fed. Proc. (1973) 32:200–205.
   Google Scholar
• CREESE I, BUTT DR, SNYDER SH: DA receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science (1976) 192:481–483.
   PubMed Web of Science ®Google Scholar
• JAVITT DC, ZUKIN SR: Recent advances in the phency-clidine model of schizophrenia. Am. J. Psych. (1991) 148:1301–1308.
   PubMed Web of Science ®Google Scholar
• TAMMINGA CA: Schizophrenia and glutamatergic transmission. Critical Rev. Neurobiol (1998) 12:21–36.
   PubMed Web of Science ®Google Scholar
• NOBLE F, ROQUES BP: CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology. Prog. Neurobiol. (1999) 58:349–379.
   PubMed Web of Science ®Google Scholar
• BISSETT G, NEMEROFF CB: The neurobiology of neurotensin. In: Psychopharmacology: The Fourth Generation of Progress. Bloom FE, Kupfer DV (Eds.), Raven Press, New York, USA (1995):573–583.
   Google Scholar
• SEEMAN P: receptor sequences. Therapeutic levels of neuroleptics occupy Dy receptors, clozapine occupies D4. Neuropsychopharmacol. (1992) 7:261–284.
   Google Scholar
• SEEMAN P, CHAU-WONG M, TEDESCO J, WONG K: Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc. Natl. Acad. Sci. USA (1975) 72:4376–4380.
   PubMed Web of Science ®Google Scholar
• LEYSEN JE, JANSSEN PM, HEYLEN L et al: Receptor interactions of new antipsychotics: relation to pharmacodynamic and clinical effects. Int. J. Psych. Clin. Practice (1998) 2: 53–A17.
   Google Scholar
• WILLIAMS GV, GOLDMAN-RAKIC PS: Modulation of memory fields dopamine D1 receptors in prefrontal cortex. Nature (1995) 376:572–575.
   PubMed Web of Science ®Google Scholar
• APOSTOLAKIS EM, GARAI J, FOX C et al.: Dopaminergic regulation of progesterone receptors: brain D5 dopamine receptors mediate induction of lordosis by agonists in rats. J. NeuroscL (1996) 16:4823–4834.
   PubMedGoogle Scholar
• SEEMAN P: Dopamine receptors and psychosis. ScL Am. (1995) 273:28–37.
   Google Scholar
• GERLACH J, LUBLIN H, PEACOCK L: Dopamine D1 receptor antagonists in rodents, in primates and in humans. In: Alfred Benzon Symposium 38: schizophrenia, an integrated view. Fog R, Gerlach J, Hemmingsen R (Eds.), Munksgaard, Copenhagen (1995):300–309.
   Google Scholar
• SEEMAN P, NIZNIK HB, GUAN H-C et al.: Link betweenD1 and D2 dopamine receptors is reduced in schizo-phrenia and Huntington's diseased brain. Proc. Natl. Acad. ScL USA (1989) 86:10156–10160.
   PubMedGoogle Scholar
• NYBERG S, NAKASHIMA Y, NORDSTROM AL et al: Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-llT2 receptor occupancy studies and clinical response. Br. J. Psychiatry (1996) Supp1.29: 40–44.
   Google Scholar
• FARDE L, HALLDIN C: D2-dopamine receptors in schizo-phrenia. In: Alfred Benzon Symposium 38: Schizophrenia, An Integrated View. Fog R, Gerlach J, Hemmingsen R (Eds.), Munksgaard, Copenhagen (1995):190–199.
   Google Scholar
• SCWARTZ J-C, LEVESQUE D, MARTRES M-P, SOKOLOFF P: Dopamine D3 receptor: basic and clinical aspects. Clin. Neuropharmacol. (1993) 16:295–314.
   PubMedGoogle Scholar
• LAHTI AC, ALBERT PK, WARFEL DT et al.: Novel antidopa-minergic strategies for the treatment of schizo-phrenia. Schizophr. Res. (1995) 15:157.
   Google Scholar
• LAHTI AC, WEILER M, CARLSSON A, TAMMINGA CA: Effects of the D3 and autoreceptor-preferring dopamine antagonist (4UH232 in schizophrenia. J. Neuronal. Transm. (1998) 105:719–734.
   PubMed Web of Science ®Google Scholar
• WAGSTAFF AJ, BRYSON HM: Clozapine: a review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs (1995) 4:370–400.
   Web of Science ®Google Scholar
• SEEMAN P, GUAN H-C, VAN TOL HHM: Dopamine D4 receptors elevated in schizophrenia. Nature (1993) 365:441–445.
   PubMed Web of Science ®Google Scholar
• TAMMINGA CA, THAKER GK, BUCHANAN R et al.: Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorode-oxyglucose and neocortical alteration with deficit syndrome. Arch. Gen. Psych. (1992) 49:522–530.
   PubMed Web of Science ®Google Scholar
• REYNOLDS GP, MANSON SL: Are striatal dopamine D4 receptors increased in schizophrenia. J. Neurochem. (1994) 63:1576–1578.
   PubMedGoogle Scholar
• STEFANIS NC, BRESNICK JN, KERWIN RW et al: Elevation of D4 dopamine receptor mRNA in postmortem schizophrenic brain. Mol. Brain Res. (1998) 53:112–119.
   PubMedGoogle Scholar
• PATEL S, FREEDMAN S, CHAPMAN KL et al.: Biological profiles of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptors. J. Pharmacol Exp. Ther. (1997) 283:636–647.
   PubMedGoogle Scholar
• BRISTOW LJ, COLLINSON N, COOK GP et al.: L-745,870, asubtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. J. Pharmacol. Exp. Ther. (1997) 283:1256–1263.
   PubMedGoogle Scholar
• MERCHANT KM, GILL GS, HARRIS DW et al. Pharma- cological characterization of U-10137, a dopamine D4 receptor selective antagonist. J. Pharmacol Exp. Ther. (1996) 279:1392–1403.
   PubMedGoogle Scholar
• MANSBACH RS, BROOKS EW, SANNER MA, ZORN SH: Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibi-tion. Psychopharmacol. (1998) 135:194–200.
   PubMedGoogle Scholar
• TALLMAN JF, PRIMUS RJ. BRODBECK R et al.: NGD94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J. Pharmacol. Exp. Ther. (1997) 282:1011–1019.
   Google Scholar
• OKUYAMA S, KAWASIMA N, CHAKI S et al.: A selective dopamine D4 receptor antagonist, NRA0160: a preclinical neuropharmacological profile. Life ScL (1999) (In Press).
   Google Scholar
• KRAMER MS, LAST B, GETSON A, REINES SA: The effects of selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch. Gen. Psych. (1997) 54:568–572.
   Google Scholar
• HOYER D, CLARKE DE, FOZARD JR et al.: International Union of Pharmacology classification of receptors for 5-hydrotryptamine (serotonin). Pharmacol Rev. (1994) 46:157–203.
   PubMed Web of Science ®Google Scholar
• GELLMAN RL, AGHAJANIAN GK: Serotonin 2 receptor-mediated excitation of interneurons in pyriform cortex: antagonism by atypical antipsychotic drugs. NeuroscL (1994) 58:515–252.
   PubMedGoogle Scholar
• SVENSSON TH, TUNG CS: Local cooling of prefrontal cortex induces pacemaker-like firing of dopamine neurons in rat ventral tegmental area in vivo. Acta. Physic)]. Scand. (1989) 136:135–136.
   PubMedGoogle Scholar
• SVENSSON TH, NOMIKOS GG, ANDERSSON JL: Modula-tion of dopaminergic neurotransmission by 5-11T2 antagonism. In: Serotonin, from cell biology to pharma-cology and therapeutics. Vanhoutte PM, Saxena PR, Paoletti R et al. (Eds.), Kluwer, Dordrecht (1993):263–270.
   Google Scholar
• PEHEK EA: Local infusion of serotonin antagonist ritanserin or IC5205 930 increases in vivo dopamine release in rat medial prefrontal cortex. Synapse (1996) 24:12–19.
   PubMedGoogle Scholar
• GLENNON RA, DUKAT M: Serotonin receptor subtypes. In: Psychopharmacology: The Fourth Generation of Progress. Bloom FE, Kupfer DV (Eds.), Raven Press, New York (1995):415–429.
   Google Scholar
• MICHAELIS EK: Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress, and aging. Prog. Neurobiol (1998) 54:369–415.
   PubMed Web of Science ®Google Scholar
• CONN PJ, PIN J-P: Pharmacology and functions of metabotropic glutamate receptors. Ann. Rev. Pharmacol. Toxicol (1997) 37:205–237.
   PubMed Web of Science ®Google Scholar
• WICKELGREN I: A new route to treating schizophrenia? Science (1998) 281:1264–1265.
   Google Scholar
• MOGHADDAM B, ADAMS BW: Reversal of phencycli-dine effects by a group II metabotropic glutamate receptor agonist in rats. Science (1998) 281:1349–1352.
   PubMed Web of Science ®Google Scholar
• •Presentation of relationship between schizophrenia and group II mGluRs.
   Google Scholar
• OKUYAMA S, NAKAZATO A: NE-100: a novel sigma receptor antagonist. CNS Drug Rev. (1996) 2:226–237.
   Google Scholar
• YAMAMOTO H, MIURA R, YAMAMOTO T et al.: Aminoacid residues in the transmembrane domain of the Type 1 sigma receptor critical for ligand binding. FEBS Lett. (1999) 445:19–22.
   PubMed Web of Science ®Google Scholar
• WEISSMAN AD, CASANOVA MF KLEINMAN JE et al.: Selective loss of cerebral cortical sigma, but not PCP binding sites, in schizophrenia. Biol. Psych. (1991) 29:41–54.
   Google Scholar
• GILLGAN PJ, TAM SW: Sigma receptor ligands: potential drugs for the treatment of CNS disorders? Drug News Perspectives (1994) 7:13–18.
   Google Scholar
• GEWIRTZ GR, GORMAM JM, VOLAVKA J et al.: BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacol. (1994) 10:37–40.
   PubMed Web of Science ®Google Scholar
• MONN JA, VALLI MJ, MASSEY SM et al.: Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3,1,0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor antagonist possessing anticonvulsant and amdolytic properties. J. Med. Chem. (1997) 40:528–537.
   PubMed Web of Science ®Google Scholar
• •Presentation of orally-active group II mGluR agonists.
   Google Scholar
• ORNSTEIN PL, BLEISCH TJ, ARNOLD MB et a/.:2-Substituted (2SR)-2-amino-2-((lsr,2sr)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group ii metabotropic glutamate receptors. 1. Effects of alkyl, arylalkyl, and diarylalkyl substitution. J. Med. Chem. (1998) 41:346–357.
   Google Scholar
• ORNSTEIN PL, BLEISCH TJ, ARNOLD MB et a/.:2-Substituted (2SR)-2-amino-2-((lsr,2sr)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group ii metabotropic glutamate receptors. 2. Effects of aromatic substitu-tion, pharmacological characterization, and bioavail-ability. J. Med. Chem. (1998) 41:358–378.
   Google Scholar
• •Presentation of orally-active group II mGluR antagonists.
   Google Scholar
• NAKAZATO A, OHTA K, SEKIGUTI Y et al.: Design, synthesis, structure-activity relationships, and biological characterization of novel arylalkoxyphen-ylalkylamin s ligands as potential antipsychotic drugs. J. Med. Chem. (1999) 42:1076–1087.
   PubMedGoogle Scholar
• NAKAZATO A, KUMAGAI T, OHTA K et al.: Synthesis and SAR of 1-alkyl-2-phenylethylamine derivatives designed from N,N-Dipropy1-4-methoxy-3-(2-phenylethoxy)phenylethylamine to discover al ligands. J. Med. Chem. (1999) 42:3965–3970.
   PubMedGoogle Scholar
• GOLDMAN-RAKIC PS: Psychopathology and neuropa-thology of prefrontal cortex in schizophrenia. In: Alfred Benzon Symposium 38: Schizophrenia, An Integrated View. Fog R, Gerlach J, Hemmingsen R (Eds.), Munksgaard, Copenhagen (1995):126–136.
   Google Scholar
• WILLIAMS GV, GOLDMAN-RAKIC PS: Modulation of memory field by dopamine Di receptors in prefrontal cortex. Nature (1995) 376:572–575.
   PubMed Web of Science ®Google Scholar
• SOKOLOFF P, GIROS B, MARTRES M-P et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature (1990) 347:146–151.
   PubMed Web of Science ®Google Scholar
• BOUTHENET M-L, SOUIL E, MARTRES MP et al: Localiza-tion of dopamine D3 receptors mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. (1991) 564:203–219.
   PubMedGoogle Scholar
• TEDESCHI DH, TEDESCHI RE, FELLOWS EJ: Central serotonin antagonist activity of a number of phenothi-azines. ArchInt. Pharmacodyn. Ther. (1961) 132:172–179.
   PubMedGoogle Scholar
• LEYSEN JE, GOMMEREN W, VAN GOMPEL P et al: Receptor binding properties in vitro and in vivo of ritanserin. A very potent and long acting serotonin-S2 antagonist. Mol. Pharmacol. (1985) 27:600–611.
   Google Scholar
• Reyntjens A, Geldders YG, HOPPENBROUWERS M-LJA et Thymostenic effects of ritanserin (R55667), a centrally acting serotonin-S2 receptor blocked. Drug Dev. Res. (1986) 8:205–211.
   Web of Science ®Google Scholar
• BERSANI G, GRISPINI A, MARINI S et al: 5HT2 antagonist ritanserin in neuroleptic-induced Parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin. Neuropharmacol (1990) 13:500–506.
   PubMedGoogle Scholar
• SORENSEN SM, KEHNE JH, FADAYEL GM et al: Charac-terization of the 5-11T2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J. Pharmacol Exp. Ther. (1993) 266:684–691.
   PubMedGoogle Scholar
• TECOTT LH, SUN LM, AKANA SF et al.: Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature (1996) 374:542–546.
   Google Scholar
• •The possible importance of 5-HT2c receptors to drug-induced weight gain, an important side effect of antipsychotics.
   Google Scholar
• GERARD C, MARTRES MP, LEFEVRE K et al.: Immunolo- calization of serotonin 5-11T6 receptor-like material in the rat central nervous system. Brain Res. (1997) 746:207–219.
   PubMed Web of Science ®Google Scholar
• ROTH BL, CRAIGO SC, CHOUDHARY MS et al,: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. (1994) 268:1403–1410.
   PubMed Web of Science ®Google Scholar
• •First presentation of the effects of psychoactive drugs at the 5-HT6 and 5-HT7 receptors.
   Google Scholar
• BOURSON A, BORRONI E, AUSTIN RH et al: Determina-tion of the role of the 5-11T6 receptor in the rat brain: a study using antisense oligonucleotides. J. Pharmacol. Exp. Ther. (1994) 274:173–180.
   Google Scholar
• SLEIGHT AJ, BOESS FG, BOURSON A et a/.:5-11T6 and 5-11T7 receptors: molecular biology, functional correlates and possible therapeutics. Drugs News & Perspectives (1997) 10:214–224.
   Google Scholar
• SCHOTTE A, JANSSEN PFN, GOMMEREN W et al.: Risperi-done compared with new reference antipsychotic drugs: in vitro and in vivo binding. Psychopharmacol (1996) 124:57–73.
   PubMed Web of Science ®Google Scholar
• GOFF DC, TSAI G, LEVITT J et al. A placebo-controlled trial of o-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry (1999) 56:21–27.
   PubMed Web of Science ®Google Scholar
• VAN BERCKEL BN, EVENBLIJ CN, VAN LOON BJ et al.: o-cycloserine increases positive symptoms in chronic schizophrenic patients when administration in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychophatmacol. (1999) 21:203–210.
   Google Scholar
• GOFF DC, HENDERSON DC, EVINS AE et al.: A placebo-controlled crossover trial of o-cycloserine added to clozapine in patients with chizophrenia. Biol. Psychiatry (1999) 45:512–514.
   PubMed Web of Science ®Google Scholar
• MAURICE T, PHAN V-L, URANI A et al.: The beneficial effects of sigmat (c7i) receptor agonists in pharmacol-ogical and pathological models of amnesia. Int. J. Neuropsychopharmacol (1998) 1:S8.
   Google Scholar
• NABESHIMA T: Pharmacology of sigma drugs developed in Japan. Int. J. Neuropsychopharmacol. (1998) 1:S7.
   Google Scholar
• DEBONNEL G, BERGERON R: Potential implication ofsigma ligands and some neurosteroids in depression. Int. J. Neuropsychopharmacol. (1998) 1:S7.
   Google Scholar